Seebri Breezhaler

Seebri Breezhaler

glycopyrronium bromide

Manufacturer:

Novartis Indonesia

Marketer:

Wellesta
Concise Prescribing Info
Contents
Glycopyrronium Br
Indications/Uses
Once-daily maintenance bronchodilator treatment to relieve symptoms in patients w/ COPD.
Dosage/Direction for Use
Recommended dose: 50 mcg once-daily inhalation at the same time of the day each day.
Special Precautions
Not for acute episodes of bronchospasm ie, as a rescue therapy. Discontinue if immediate hypersensitivity reactions; paradoxical bronchospasm occurs. Narrow-angle glaucoma or urinary retention; unstable ischaemic heart disease, left ventricular failure, history of MI & long QT syndrome or prolonged QTc, arrhythmia (excluding chronic stable atrial fibrillation). Patients w/ rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Monitor closely patients w/ severe renal impairment including those w/ ESRD requiring dialysis for potential AR. Pregnancy & lactation. Not to be used in childn <18 yr.
Adverse Reactions
Dry mouth, gastroenteritis; insomnia. Nasopharyngitis, vomiting, musculoskeletal & neck pain, DM. Elderly >75: UTI & headache.
Drug Interactions
Not recommended w/ anticholinergic-containing drugs.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03BB06 - glycopyrronium bromide ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, anticholinergics.
Presentation/Packing
Form
Seebri Breezhaler inhalation powd cap 50 mcg
Packing/Price
((+ inhaler)) 3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in